title: Sequential treatment with monofluorophosphate and zoledronic acid in osteoporotic rats.
abstract: OBJECTIVE
  Osteoporosis is the consequence of an imbalance in bone remodeling caused by excessive resorption or inappropriate bone formation. This paper proposes a sequential treatment with monofluorophosphate (MFP) and zoledronic acid (Z), together with changes in the calcium content in the diet.
  
  
  METHODS
  Seven-week-old female Sprague Dawley rats were divided into five groups (n = 21 per group): (1) sham-operated rats (Sham); (2) ovariectomized (OVX) rats fed with a normal calcium diet (OVX); (3) OVX rats fed with a normal calcium diet and treated sequentially with monofluorophosphate and zoledronic acid (OVX.G1); (4) OVX rats sequentially fed with a low calcium diet and then a high calcium diet, without treatment (OVX.G2); (5): OVX rats fed with a low calcium diet and then a high calcium diet, treated sequentially with monofluorophosphate and zoledronic acid (OVX.G3).
  
  
  RESULTS
  After 150 days, the OVX.G3 group showed a similar bone volume to that of the Sham group due to an increase in trabecular number. Dual X-ray absorptiometry bone analysis showed an increase of 9.8% compared with OVX rats. Additionally, an increase in the fracture load at the cortical bone and higher fracture load, ultimate load and stiffness in the compression test were found.
  
  
  CONCLUSIONS
  The sequential treatment with monofluorophosphate and zoledronic acid increases trabecular bone mass, bone mineral density and bone strength.
authors.affiliation: * Bone Biology Laboratory, School of Medicine, Rosario National University , Rosario.
authors.forename: M L
authors.initials: ML
authors.lastname: Brance
authors.forename: L R
authors.initials: LR
authors.lastname: Brun
authors.forename: V E
authors.initials: VE
authors.lastname: Di Loreto
authors.forename: M
authors.initials: M
authors.lastname: Lupo
authors.forename: A
authors.initials: A
authors.lastname: Rigalli
mesh_terms: D000818:Animals; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000008:administration & dosage; D016723:Bone Remodeling / Q000187:drug effects*; D002136:Calcium, Dietary / Q000008:administration & dosage*; D004164:Diphosphonates / Q000008:administration & dosage*; D004195:Disease Models, Animal; D005260:Female; D005459:Fluorides / Q000008:administration & dosage*; D007093:Imidazoles / Q000008:administration & dosage*; D010024:Osteoporosis / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology; D058866:Osteoporotic Fractures / Q000517:prevention & control; D010052:Ovariectomy / Q000009:adverse effects*; D010710:Phosphates / Q000008:administration & dosage*; D051381:Rats; D017207:Rats, Sprague-Dawley; D016896:Treatment Outcome; D000077211:Zoledronic Acid
chemical_list: D050071:Bone Density Conservation Agents; D002136:Calcium, Dietary; D004164:Diphosphonates; D007093:Imidazoles; D010710:Phosphates; C012980:fluorophosphate; D000077211:Zoledronic Acid; D005459:Fluorides
keywords: BONE MASS; BONE STRENGTH; MONOFLUOROPHOSPHATE; OSTEOPOROSIS; ZOLEDRONIC ACID